News archive
Showing 688 results
September 2016
-
Media Release
Novartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions
- Ilaris® (canakinumab) is the first and only FDA-approved biologic treatment for patients with TRAPS, HIDS/MKD and FMF(1)- These three simultaneous approvals conducted under FDA Priority Review… -
Media Release
Novartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions
-
Media Release
Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients
New analysis of PARADIGM-HF data shows that among patients who had been hospitalized for heart failure, those on Entresto reported higher relative health-related quality of life (HRQL) scores… -
Media Release
Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients
-
Media Release
Novartis BAF312 reduced the risk of disability progression in pivotal phase III study in secondary progressive MS patients
-- EXPAND study data presented at ECTRIMS 2016 show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs. placebo in patients with… -
Media Release
Novartis BAF312 reduced the risk of disability progression in pivotal phase III study in secondary progressive MS patients
-
Media Release
Novartis data finds relapsing MS patients on Gilenya® had greater treatment retention and satisfaction rates vs. injectable DMTs
- In a well-controlled, randomized, open-label study, Gilenya patients had higher treatment retention rates at one year, 81.3% vs. those on injectable DMTs, 29.2% - Throughout the study almost 10… -
Media Release
Novartis data finds relapsing MS patients on Gilenya® had greater treatment retention and satisfaction rates vs. injectable DMTs
July 2016
-
Media Release
Novartis announces FDA approval of Xolair® (omalizumab) for pediatric allergic asthma
-- Extension of indication makes Xolair the first and only approved biologic for pediatric patients six years and older with uncontrolled moderate to severe persistent allergic asthma-- Asthma is one… -
Media Release
Novartis announces FDA approval of Xolair® (omalizumab) for pediatric allergic asthma
June 2016
-
Media Release
Largest global psoriasis survey shows 85% of U.S. respondents faced social stigma like discrimination and humiliation because of their skin
- Global survey, including more than 1,400 U.S. moderate-to-severe psoriasis patients, is the first to look at perceptions of clear skin1- Despite the significant impact of living with the disease,… -
Media Release
Largest global psoriasis survey shows 85% of U.S. respondents faced social stigma like discrimination and humiliation because of their skin